Literature DB >> 27411833

The Emerging Role of Regucalcin as a Tumor Suppressor: Facts and Views.

C V Vaz, S Correia, H J Cardoso, M I Figueira, R Marques, C J Maia, S Socorro1.   

Abstract

Regucalcin (RGN) is a multifunctional protein that was first described as a calcium (Ca2+)-binding protein playing a relevant role in the maintenance of intracellular Ca2+ concentration. However, due to its downregulated expression with aging, RGN is also known as senescence marker protein-30. The RGN protein is an X-chromosome gene product, whose transcription is regulated by a myriad of hormonal and non-hormonal factors. Besides the well-known role in Ca2+ homeostasis, RGN has also been linked to the control of several intracellular signaling pathways, and basic biological processes, such as oxidative stress, cell proliferation, apoptosis, and metabolism. RGN has been shown to have antioxidant properties by its activity reducing the production of reactive oxygen species and increasing the antioxidant defenses. The role of RGN suppressing cell proliferation is associated with the regulation of expression of oncogenes and tumor suppressor genes. It results clear that all the existent knowledge implicates RGN in the control of the main biological processes actually recognized as the hallmarks of cancer. Moreover, it has been shown that tumor onset and progression are underpinned by the loss of RGN expression, whereas RGN overexpression showed to have a protective role against the development of chemicallyinduced tumors. This review describes the mechanisms that control the tissue expression of RGN and discusses the experimental evidence that indicate RGN as a new tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27411833     DOI: 10.2174/1566524016666160714124550

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  4 in total

1.  Regucalcin promotes dormancy of prostate cancer.

Authors:  Sambad Sharma; Xinhong Pei; Fei Xing; Shih-Ying Wu; Kerui Wu; Abhishek Tyagi; Dan Zhao; Ravindra Deshpande; Marco Gabriel Ruiz; Ravi Singh; Feng Lyu; Kounosuke Watabe
Journal:  Oncogene       Date:  2020-12-15       Impact factor: 9.867

2.  A mechanism of regucalcin knock-down in the promotion of proliferation and movement of human cervical cancer HeLa cells.

Authors:  Xiaolong Li; Yingwen Huang; Pengfei Wang; Wei Song; Qingmei Yao; Qiping Hu; Sufang Zhou
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

3.  Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer.

Authors:  Changjian Shao; Kai Guo; Liqun Xu; Yimeng Zhang; Hongtao Duan; Yingtong Feng; Minghong Pan; Di Lu; Xiaoya Ren; Apar Kishor Ganti; Taiki Hakozaki; Jing Han; Xiaolong Yan; Zhiqiang Ma
Journal:  Transl Lung Cancer Res       Date:  2021-12

4.  Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family.

Authors:  Abhishek Kumar; Obul Reddy Bandapalli; Nagarajan Paramasivam; Sara Giangiobbe; Chiara Diquigiovanni; Elena Bonora; Roland Eils; Matthias Schlesner; Kari Hemminki; Asta Försti
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.